Boston Scientific Corp. received a split decision from a U.K. patent court in its transcatheter aortic valve replacement (TAVR) patent infringement lawsuit against Edwards Lifesciences Corp. The court determined one of Marlborough, Mass.-based Boston Scientific's patents asserted against Edwards is valid and infringed. The court also ruled that a second patent related to the outer seals for the technology was found to be invalid. Boston Scientific has developed the Lotus Valve for TAVR, which received approval in Europe back in 2013, but has yet to receive a nod from the FDA. Irvine, Calif.-based Edwards' Sapien...

Boston Scientific Corp. received a split decision from a U.K. patent court in its transcatheter aortic valve replacement (TAVR) patent infringement lawsuit against Edwards Lifesciences Corp.

Tandem Diabetes Care Inc. has developed a tool for the remote deployment of its insulin pump software. The device updater will allow diabetes patients with the t:slim insulin delivery system to have access to new features, without having to wait on reimbursement to buy a new pump. Provisions of a patient's insurance plan typically limit eligibility for a new pump. Patients are often unable to receive the benefits of any new innovations or features that come out after they've received pumps. But the San Diego-based company's remote deployment tool allows patients to receive updates throughout...

Tandem Diabetes Care Inc. has developed a tool for the remote deployment of its insulin pump software. The device updater will allow diabetes patients with the t:slim insulin delivery system to have access to new features, without having to wait on reimbursement to buy a new pump.

Liquid biopsy startup Grail Inc. said it has raised more than $900 million through the first close of its series B round, putting it on the path to develop a blood-based test for cancer screening. The Menlo Park, Calif.-based company is slated to bring in more than $1 billion in the round and could close on the remainder of the investment prior to the end of 1Q17. Arch Venture Partners led the financing, with participation from Johnson & Johnson Innovation, Amazon Inc., Bristol-Myers Squibb Inc., Celgene Corp., Varian Medical Systems Inc. and Merck & Co....